BR112013026447A2 - métodos para a regulação da expressão de gene de sirtuína - Google Patents

métodos para a regulação da expressão de gene de sirtuína

Info

Publication number
BR112013026447A2
BR112013026447A2 BR112013026447A BR112013026447A BR112013026447A2 BR 112013026447 A2 BR112013026447 A2 BR 112013026447A2 BR 112013026447 A BR112013026447 A BR 112013026447A BR 112013026447 A BR112013026447 A BR 112013026447A BR 112013026447 A2 BR112013026447 A2 BR 112013026447A2
Authority
BR
Brazil
Prior art keywords
methods
gene expression
sirtuin gene
regulating sirtuin
regulating
Prior art date
Application number
BR112013026447A
Other languages
English (en)
Inventor
Rondo Paul Middleton
Yuanlong Pan
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112013026447A2 publication Critical patent/BR112013026447A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Saccharide Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

resumo patente de invenção: "métodos para a regulação da expressão de gene de sirtuína". a presente invenção fornece os métodos úteis para a regulação da expressão de gene de sirtuína, simular a restrição calória, prevenir e tratar o mal de alzheimer, aumentar a longevidade e retardar o envelhecimento em um animal. os métodos compreendem a administração de uma ou mais isoflavonas aos animais, de preferência nas quantidades a partir de cerca de 0,001 a cerca de 10 g/ kg/ dia.
BR112013026447A 2011-04-15 2012-03-26 métodos para a regulação da expressão de gene de sirtuína BR112013026447A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161517228P 2011-04-15 2011-04-15
PCT/US2012/030509 WO2012141876A1 (en) 2011-04-15 2012-03-26 Methods for regulating sirtuin gene expression

Publications (1)

Publication Number Publication Date
BR112013026447A2 true BR112013026447A2 (pt) 2016-10-18

Family

ID=47009640

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026447A BR112013026447A2 (pt) 2011-04-15 2012-03-26 métodos para a regulação da expressão de gene de sirtuína

Country Status (11)

Country Link
US (1) US20140039047A1 (pt)
EP (2) EP2898923A3 (pt)
JP (1) JP6140682B2 (pt)
CN (1) CN103596563A (pt)
AU (1) AU2012243210B2 (pt)
BR (1) BR112013026447A2 (pt)
CA (1) CA2832234A1 (pt)
MX (1) MX2013011996A (pt)
RU (1) RU2603749C2 (pt)
WO (1) WO2012141876A1 (pt)
ZA (1) ZA201308585B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102016078B1 (ko) 2012-11-30 2019-08-30 (주)아모레퍼시픽 심장 질환 예방 또는 치료용 조성물
US20170326100A1 (en) * 2014-12-09 2017-11-16 Amorepacific Corporation Composition for activating longevity gene
TWI556818B (zh) * 2015-08-07 2016-11-11 長庚大學 哺乳類sirt1的活化劑
WO2021068242A1 (en) * 2019-10-12 2021-04-15 Shenzhen University An agent that enables sirt7 gene expression and the use thereof
CN111450098A (zh) * 2020-04-20 2020-07-28 中国科学院动物研究所 拉米夫定在延缓衰老中的应用以及制备用于筛选延缓衰老药物的细胞模型
JPWO2021230145A1 (pt) * 2020-05-11 2021-11-18
US20230310367A1 (en) * 2020-09-04 2023-10-05 Daicel Corporation Composition for enhancing nampt gene expression
CN115429810B (zh) * 2021-06-03 2024-03-08 苏州禾研生物技术有限公司 异黄酮类化合物在制备预防或治疗酒精性肝损伤或解酒保肝的药物中的用途
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US5952033A (en) 1996-12-24 1999-09-14 Nestec S.A. Gelatinized cereal product containing oligosaccharide and processes of preparing and using same
PT862863E (pt) 1997-01-09 2002-04-29 Nestle Sa Produto cerealifero contendo probioticos
US6359017B1 (en) * 1999-02-24 2002-03-19 Geza Bruckner Dietary compositions and methods
BR0013780A (pt) 1999-09-07 2002-05-14 Nestle Sa Processo de melhoramento da pele e da pelagem de animais de estimação
ES2261259T3 (es) 1999-09-22 2006-11-16 Societe Des Produits Nestle S.A. Procedimiento para incrementar la actividad de los animales domesticos.
EP1541673B1 (en) 2000-05-25 2007-04-04 Société des Produits Nestlé S.A. Probiotics for pet food applications
ES2269406T3 (es) 2000-05-26 2007-04-01 Societe Des Produits Nestle S.A. Producto alimenticio para animales domesticos.
GB0027761D0 (en) 2000-11-14 2000-12-27 Nestle Sa Nutritional composition for an immune condition
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
CA2504682A1 (en) * 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
AU2005224017B2 (en) * 2004-03-17 2010-12-16 Société des Produits Nestlé S.A. Compositions and methods for reducing or preventing obesity
PT1755391E (pt) * 2004-06-04 2016-02-03 Univ Washington Métodos e composições para o tratamento de neuropatias
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
AU2006206274A1 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1956923A1 (en) * 2005-11-02 2008-08-20 Nestec S.A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
US8242100B2 (en) * 2006-02-28 2012-08-14 Nestec Sa Compositions and methods for inducing bone growth and inhibiting bone loss
US20080108696A1 (en) * 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
CN101200459A (zh) * 2006-12-11 2008-06-18 南京莱尔生物化工有限公司 一种雌马酚的合成方法

Also Published As

Publication number Publication date
AU2012243210B2 (en) 2016-07-14
RU2013150828A (ru) 2015-05-20
WO2012141876A1 (en) 2012-10-18
EP2898923A2 (en) 2015-07-29
EP2898923A3 (en) 2015-10-07
MX2013011996A (es) 2013-11-01
CA2832234A1 (en) 2012-10-18
JP6140682B2 (ja) 2017-05-31
EP2696692A1 (en) 2014-02-19
AU2012243210A1 (en) 2013-10-24
JP2014516359A (ja) 2014-07-10
US20140039047A1 (en) 2014-02-06
RU2603749C2 (ru) 2016-11-27
ZA201308585B (en) 2015-06-24
CN103596563A (zh) 2014-02-19
EP2696692A4 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
BR112013026447A2 (pt) métodos para a regulação da expressão de gene de sirtuína
BR112016010166A2 (pt) métodos para usar interleucina-10 para tratar doenças e distúrbios
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
BR112013030894A2 (pt) moduladores do sistema imune
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112016029713A2 (pt) métodos para o tratamento de sobrepeso ou obesidade
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
BR112014029301A2 (pt) métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta
BR112014006587A2 (pt) modulação antisense da expressão de gcgr
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112014017626A2 (pt) métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112014003704A2 (pt) moduladores ror gama
GT201400069A (es) Composiciones farmaceuticas
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
BR112012008238A2 (pt) métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais.
BR112015017775A2 (pt) enzima cistationina beta-sintase para o tratamento de homocistinúria
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
BR112015003680A2 (pt) métodos para controle de perda de peso e massa corpórea

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2507 DE 22-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.